Vertex Pharmaceuticals

We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Estonia. This new agreement will enable broad access for eligible people living with CF ages 6 years and older from October 1, 2026.

We announced positive Phase 2b AMPLIFIED results and completion of enrollment in the Phase 2/3 AMPLITUDE trial for people living with APOL1-mediated kidney disease. Learn more: news.vrtx.com/news-releases/…

We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Latvia. This new agreement has enabled broad access for eligible people living with CF ages 6 years and older since August 17, 2026.

Extended reimbursement agreement with health authorities in #Uruguay: Since July 2026 eligible children living with #CysticFibrosis ages 2 years and older have broad access to one of our medicines.

Today we announced an agreement to acquire @Crinetics. This deal adds to our portfolio of transformative medicines & leverages our strengths in R&D & commercialization to bring more potentially best-in-class medicines to patients with serious diseases. news.vrtx.com/news-releases/…

A landmark update for children living with #SickleCellDisease or #TransfusionDependentBetaThalassemia: The @US_FDA has approved a label extension for our #CRISPR-based therapy. Learn more: news.vrtx.com/news-releases/…

We presented data on our gene-edited therapy for people with sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Congress and announced regulatory submissions for potential future use in additional patients. Find out more: vrtx.com/en-global/ We’re grateful to the researchers, clinicians, and patients whose contributions help move the science forward. #EHA2026

Extended reimbursement agreement with National Health Insurance Fund in #NorthMacedonia: Since May 20, 2026, eligible people living with #CysticFibrosis ages 2 years and older have broad access to one of our medicines.

We are proud to announce that the U.S. FDA has accepted our Biologics License Application (BLA) for our investigational therapy for #IgANephropathy. Learn more: news.vrtx.com/news-releases/…

First reimbursement agreement in #Chile: Eligible people living with #CysticFibrosis now have reimbursed access to one of our #CysticFibrosis therapies.

Major update for the treatment of cystic fibrosis (CF) in the U.S.: The FDA has approved the label extension for our triple combination therapies, expanding availability of these medicines to ~95% of all people with CF in the U.S. Learn more: news.vrtx.com/news-releases/…

We’re excited to share positive topline results from the interim analysis of the RAINIER Phase 3 study of our investigational therapy for #IgANephropathy. Learn more: news.vrtx.com/news-releases/…

We’re pleased to share results from the Phase 4 study of our non‑opioid treatment for moderate‑to‑severe acute pain, presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting: news.vrtx.com/news-releases/…

Announcing a reimbursement agreement with the Italian Medicines Agency (AIFA) for access to our latest cystic fibrosis (CF) therapy for eligible patients 6 years and older and expanded access to two of our other medicines for eligible patients 2 years old and older.

Vertex is committed to the safety and security of all job seekers. If you receive suspicious recruitment messages or believe you have been targeted by a recruitment scam, do not respond or provide any information. Learn how to identify recruitment scams: vrtx.com/beware-recruitment-…

We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Bulgaria. This new agreement has enabled broad access for eligible people living with CF ages 6 years and older since Jan 5, 2026.

Extended reimbursement agreement with the Croatian health authorities: Since Dec 30, 2025, eligible children living with #CysticFibrosis ages 1 year and older have had broad access to some of our medicines.

We are pleased to share new data from multiple studies of our gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia at the 67th ASH Annual Meeting this weekend. Learn more: news.vrtx.com/news-releases/… #ASH25

Extended reimbursement agreement with the health authorities of #Slovakia: eligible people living with #CysticFibrosis ages 2 year and older will now have broad access to one of our medicines.

We're excited to share several advancements across our investigational programs for the potential treatment of IgA nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). Learn more: investors.vrtx.com/news-rele…